Skip to Content

Syros Pharmaceuticals Inc SYRS Stock Quote

| Rating as of

Morningstar‘s Stock Analysis SYRS

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics SYRS

Company Profile SYRS

Business Description

Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. It is primarily involved in the segments of the pharmaceutical, biotechnology, and other related markets that address gene control and cancer. The Company operates only in the United States.

Contact
35 CambridgePark Drive, 4th Floor
Cambridge, MA, 02140
T +1 617 744-1340
Industry Biotechnology
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Stock Type Distressed
Employees 124